Semaglutide Dosage Guide

95/100 confidence

Complete guide to Semaglutide dosing protocols, administration methods, and safety considerations for research purposes.

Dosage Overview

Dose per Injection

250 mcg – 2.4 mg

Frequency

Once per week

Route

subcutaneous or oral

Cycle Length

16–52 weeks

Detailed Dosage Information

For weight management (Wegovy)

start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly.

Each escalation lasts 4 weeks.

Maintenance dose is 2.4 mg weekly.

For type 2 diabetes (Ozempic)

start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg.

May increase to 1 mg, then 2 mg if additional glycemic control is needed.

Oral semaglutide (Rybelsus)

3 mg daily for 30 days, then 7 mg daily.

May increase to 14 mg daily.

Oral Wegovy

3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily.

Take on empty stomach with no more than 4 oz of water, 30 minutes before food.

Administration Method

Injectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets.

Research Backing

STEP 1-5 trials (weight management), SUSTAIN 1-10 trials (T2D), SELECT trial (cardiovascular outcomes, NEJM 2023). Over 10,000 clinical trial participants across pivotal studies. FDA-approved since 2017 (Ozempic), 2021 (Wegovy).

Side Effects to Monitor

Very common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions.

Safety Considerations & Risks

Black box warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Risk of pancreatitis — discontinue if suspected. Potential for gallbladder-related events (cholelithiasis, cholecystitis). Risk of hypoglycemia when combined with insulin or sulfonylureas. Muscle loss: 20-40% of weight lost may be lean mass. Suicidal ideation reports are under FDA review. Not recommended in pregnancy.